Current Alzheimer Research
December 1, 2022
Ayse Hande Arpacı, Hasan Çalıskan, Emel Gunes et al.
Background: Ketamine is a widely used anesthetic agent. Although the potential adverse effects of ketamine use in juvenile age are uncertain, certain studies reported that children exposed to recurrent anesthesia could face an increased risk of neurodevelopmental deficits in motor function and behavioral risks. We aimed to investigate the long-term effects of repeated exposure to various...
The Journal of Clinical Psychiatry
November 14, 2022
Anna Feeney, Bettina B. Hoeppner, Marlene P. Freeman et al.
9 citations
Objective: Ketamine is a novel and rapidly acting treatment for major depressive disorder (MDD). Benzodiazepines are commonly coprescribed with antidepressants in MDD. This study sought to examine data from a randomized clinical trial that compared a single infusion of intravenous (IV) ketamine to midazolam placebo in treatment-resistant depression (DSM-IV-TR MDD) and to assess whether the use...
Pharmaceuticals (Basel, Switzerland)
November 9, 2022
Sabrina de Carvalho Cartágenes, Cinthia Cristina Sousa de Menezes Da Silveira, Bruno Gonçalves Pinheiro et al.
Ketamine, also called 'K-powder' by abusers, an analog of phencyclidine, primarily acts as an antagonist of N-methyl-D-aspartic acid (NMDA) receptors, therapeutically used as an anesthetic agent. Ketamine also stimulates the limbic system, inducing hallucinations and dissociative effects. At sub-anesthetic doses, ketamine also displays hallucinatory and dissociative properties, but not loss of...
BMC Psychiatry
October 3, 2022
S. Ahuja, Madeline Brendle, Leo Smart et al.
Background Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics. However, a characterization of the outpatient population receiving IM ketamine treatment and an evaluation of the real-world depression, anxiety, and safety outcomes...
Frontiers in Psychiatry
September 28, 2022
K. Hassan, W. Struthers, Aditya Sankarabhotla et al.
25 citations
Intravenous and intranasal ketamine have been shown to be effective therapeutic options in patients suffering from treatment-resistant depression (TRD). The use of sublingual (SL), rapid dissolve ketamine tablets (RDT) offers a novel approach for delivery for mental health indications. This study assessed the effectiveness and safety of self-administration of off-label, SL, rapid dissolve...
Journal of Clinical Psychiatry
September 12, 2022
P. Oliver, A. Snyder, R. Feinn et al.
Introduction: Few studies have been published to date exploring the effectiveness of ketamine for treatment-resistant depression (TRD) in large clinical samples. We report on the clinical outcomes of a large cohort treated with ketamine as part of clinical practice. Methods: Deidentified electronic chart data were obtained from a multisite private ketamine infusion clinic for 424 patients with...
Journal of Studies on Alcohol and Drugs
July 1, 2022
Timothy I. Michaels, Lebert Lester, Sara de la Salle et al.
19 citations
OBJECTIVE: Despite strong evidence for the safety and efficacy of ketamine in the treatment of mood disorders, the enrollment of Black, Indigenous, and People of Color (BIPOC) has not been a focus of this research. Health disparities in the treatment of mood disorders in BIPOC indicate a strong need to understand the clinical, social, and pharmacological aspects of this novel treatment in...
Journal of Affective Disorders
July 1, 2022
Thomas D Hull, Matteo Malgaroli, Adam Gazzaley et al.
59 citations
BACKGROUND At-home Ketamine-assisted therapy (KAT) with psychosocial support and remote monitoring through telehealth platforms addresses access barriers, including the COVID-19 pandemic. Large-scale evaluation of this approach is needed for questions regarding safety and effectiveness for depression and anxiety. METHODS In this prospective study, a large outpatient sample received KAT over...
Front Pain Res (Lausanne)
June 27, 2022
Dianna E. Willis, Peter A. Goldstein
6 citations
The phencyclidine-derivative ketamine [2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one] was added to the World Health Organization's Model List of Essential Medicines in 1985 and is also on the Model List of Essential Medicines for Children due to its efficacy and safety as an intravenous anesthetic. In sub-anesthetic doses, ketamine is an effective analgesic for the treatment of acute pain...
European Psychiatry
June 1, 2022
M. Turki, O. Abidi, S. Ellouze et al.
1 citation
Introduction Ketamine is routinely used for anesthetic induction because of its dissociative properties. Recently, it has attracted attention as a rapid-acting anti-depressant, but other studies have also reported its efficacy in the management of diverse psychiatric pathologies previously resistant to treatment. Objectives We aimed to review the efficacity of ketamine in the management of...